Parse Biosciences

Parse Biosciences (operating at parsebiosciences.com) is a global life sciences company engineered for scalable single-cell sequencing. Founded in 2018 by Alex Rosenberg, Ph.D., and Charles Roco, Ph.D., and headquartered in Seattle, Washington, Parse Biosciences addresses the limitations of traditional microfluidics approaches in single-cell analysis. Under the hood, its Evercode™ technology enables high-throughput single-cell RNA sequencing without the need for expensive, specialized instruments, offering a cost-effective and accessible alternative to existing solutions. This allows researchers and labs to conduct large-scale experiments with greater flexibility and efficiency. Backed by over $100 million in total funding, including a $50 million round announced in 2024, the company continues to expand its reach, with technologies now used in more than 3,000 labs worldwide.